Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397722 · ClinicalTrials.gov registry record · Phase 2
Treatment Of Patients With Social Anxiety Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT00397722: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00397722 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 299 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (125% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397722, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
Primary Outcome
The LSAS is an investigator-rated scale consisting of 48 questions concerning various social situations. The LSAS is the first psychiatric assessment at all post-screening visits. A qualified independent efficacy rater scored the participant's "fear or anxiety" and "avoidance" of social situations on 4-point scale : where, 0= None, 1= Mild, 2= Moderate, 3= Severe. Scores were recorded in participant's source documents. The LSAS total score was the sum of each of the forty-eight individual respon
Interventions
- DRUG paroxetine
- DRUG GW876008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2006-11-09 |
| Est. Completion | 2007-09-05 |
| Phase | Phase 2 |
What the finished NCT00397722 record still lists
NCT00397722 is an interventional study that assigns participants to a tested intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (125% higher).
The record links to 0 conditions, and to 2 interventions - of which paroxetine is the first listed.
NCT00397722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00397722 about?
NCT00397722 is a clinical study titled "Treatment Of Patients With Social Anxiety Disorder". GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
What is the current status of trial NCT00397722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2006-11-09. Estimated completion is 2007-09-05.
What interventions are being tested in trial NCT00397722?
The interventions under investigation include: paroxetine (DRUG), GW876008 (DRUG).
Who is sponsoring clinical trial NCT00397722?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00397722's enrollment target sits among peer trials
299 188th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI